Edison Partners leads $21 million funding round for clinical trial intelligence disruptor Lokavant

Rhea-AI Summary

Edison Partners has led a $21 million funding round for Lokavant, a clinical trial intelligence company. The investment aims to enhance Lokavant's platform, which integrates clinical trial data for effective planning and execution. Roivant Sciences (Nasdaq: ROIV) also participated in this funding, which follows a year of triple-digit growth for Lokavant. The company intends to expand its commercial teams and accelerate feature development to meet the growing demand from pharmaceutical firms seeking faster drug development solutions.

Positive

• Secured $21 million investment to enhance platform capabilities.
• Triple-digit growth in 2022 indicates strong market demand.
• Participation of Roivant Sciences adds credibility and potential strategic alignment.

Negative

• None.

Investment will transform the clinical research industry for smarter and faster trials

PRINCETON, N.J. and NEW YORK, Dec. 7, 2022 /PRNewswire/ -- Edison Partners, a leading growth equity investment firm, today announced it is leading a $21 million investment round in Lokavant, the leading clinical trial intelligence company.

Lokavant will use the funds to scale its commercial teams, and accelerate feature development for its platform, which provides intelligence for clinical trials from planning to execution. As part of the transaction, Edison's General Partner, Gregg Michaelson, will join Lokavant's board of directors.

Roivant Sciences (Nasdaq: ROIV), which develops transformative medicines and technologies by building agile, focused companies called Vants, will also participate in the investment round. This fundraising round was concluded on the back of triple-digit growth in 2022, as pharmaceutical companies and their contract research organization partners seek new ways of expediting novel therapeutics development.

Lokavant has developed a clinical trial intelligence platform that enables the real-time integration and harmonization of all clinical trial data for study planning and operations. These data are augmented by a market-leading proprietary Lokavant data set of more than 2,000 trials, as well as best-in-class third-party data, to generate predictive insights on trial operations and conduct.

Clinical researchers access the platform via use-case-specific applications, with a product portfolio encompassing data-driven study planning, benchmarking, operational health assessments, risk detection, medical monitoring, and vendor oversight, all incorporating Lokavant's proprietary data set into planning and monitoring.

"Our collaboration with Edison Partners validates Lokavant's mission to make clinical trials smarter using our proprietary data and industry-leading Clinical Trial Intelligence Platform," said Lokavant CEO and co-founder, Rohit Nambisan. "Especially in today's challenging fundraising environment, this milestone is a testament to our platform's ability to address the significant issues present in planning and conducting complex global clinical trials. With significant growth in 2022, we are excited to expand our data ecosystem and accelerate our go-to-market strategy, partnering with best-in-class pharmaceutical and biotechnology organizations on their most pressing study planning and execution challenges."

Lokavant was incubated by Roivant Health and piloted with numerous Roivant biotech "Vants" as customers. "We're excited to work with Edison to help support Lokavant in its next phase of growth," said Alex Gasner, EVP of Roivant Health. "At Roivant, we believe all clinical trial decisions, from study planning to execution, must be supported by high-quality, consistent data. This round of financing will support Lokavant's mission to reduce the time and cost of drug development by using data in every aspect of clinical decision-making."

"Edison Partners' previous successes investing in real-world data and evidence platforms along with our experience in PharmaTech led us to seek out a clinical trial solution that helps to improve outcomes, reduce cost, and take patient satisfaction to the next level. It became clear that the Lokavant solution would provide us with an opportunity to replicate that success," said Edison's General Partner, Gregg Michaelson. "We believe Lokavant's best-in-class product and data platform, combined with Edison's investment and operating expertise, will result in a leading clinical trial intelligence business very quickly. It's far more than just a first-mover advantage; it's truly differentiated technology along with Rohit's strong leadership and domain expertise that's going to make Lokavant a winner."

About Edison Partners
Edison Partners is a leading growth equity firm providing the financial and intellectual capital that CEOs and their executive teams need to grow and scale their companies. The firm's team brings more than 275 years of combined investing, operating and sector experience to each investment, accessible via the Edison Edge value creation platform, which is tailored to each business' strategy, stage and operating needs. Edison targets high-growth financial technology, healthcare IT and vertical SaaS and marketplace companies located outside Silicon Valley with $10 million to $30 million in revenue. Investments also include buyouts, recapitalizations, spinouts, and secondary stock purchases. Edison's active portfolio has created aggregated market value exceeding $10 billion. Edison Partners manages $1.6 billion in assets as of September 30, 2022. For more information on Edison Partners, please visit edisonpartners.com and follow on LinkedIn.

About Lokavant
Lokavant is a clinical intelligence platform that improves the time, cost, and quality of trial planning and execution through data-driven analytics applications. Lokavant's platform aggregates and integrates real-time data from disparate trial data sources, and powers advanced analytics enabled by its compendium of proprietary trial data. The suite of applications built on the platform allows study teams to proactively plan and manage their studies and surface insights, driving efficiencies in all scientific and operational use cases. Email contact@lokavant.com to learn more or visit www.lokavant.com.

About Roivant
Roivant's mission is to improve the delivery of healthcare to patients by treating every inefficiency as an opportunity. Roivant develops transformative medicines faster by building technologies and developing talent in creative ways, leveraging the Roivant platform to launch Vants – nimble and focused bio-pharmaceutical and health technology companies. For more information, please visit www.roivant.com.

Media Contact:
Katie Morales
Bospar for Edison Partners
prforedison@bospar.com

Media Contact:
press@lokavant.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/edison-partners-leads-21-million-funding-round-for-clinical-trial-intelligence-disruptor-lokavant-301696143.html

SOURCE Lokavant

FAQ

What is the purpose of the $21 million investment in Lokavant?

The investment will support Lokavant in scaling its commercial teams and accelerating platform feature development for clinical trials.

How does Lokavant's platform benefit clinical trials?

Lokavant's platform integrates and harmonizes clinical trial data for improved planning and execution, leading to faster drug development.

What role does Roivant Sciences play in the funding round?

Roivant Sciences participated in the funding round, showcasing its commitment to innovative drug development solutions.

What growth did Lokavant experience in 2022?

Lokavant reported triple-digit growth in 2022, driven by increased demand from pharmaceutical companies for efficient trial solutions.

Who led the investment round for Lokavant?

The investment round was led by Edison Partners, a prominent growth equity firm.